Patients with NSCLC may display a low ratio of p.T790M vs. activating EGFR mutations in plasma at disease progression: implications for personalised treatment

INTRODUCTION: NSCLC harboring activating mutations of EGFR is highly sensitive to first-line EGFR-tyrosine kinase inhibitors (TKIs), but drug resistance depending on the EGFR mutation p.T790M will occur in about 50-60% of patients. Detailed information on the amount of p.T790M plasmatic level associ...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Re, Marzia, Bordi, Paola, Petrini, Iacopo, Rofi, Eleonora, Mazzoni, Francesca, Belluomini, Lorenzo, Vasile, Enrico, Restante, Giuliana, Di Costanzo, Francesco, Falcone, Alfredo, Frassoldati, Antonio, van Schaik, Ron H.N., Steendam, Christi M.J., Chella, Antonio, Tiseo, Marcello, Morganti, Riccardo, Danesi, Romano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689667/
https://www.ncbi.nlm.nih.gov/pubmed/29156777
http://dx.doi.org/10.18632/oncotarget.20947

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5689667/
https://www.ncbi.nlm.nih.gov/pubmed/29156777
http://dx.doi.org/10.18632/oncotarget.20947

Ejemplares similares